In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin. Among patients with HER2-positive early breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback